Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating)’s stock price hit a new 52-week high on Thursday following a stronger than expected earnings report. The stock traded as high as $81.00 and last traded at $71.99, with a volume of 32651 shares trading hands. The stock had previously closed at $75.89.
The medical equipment provider reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.25. The firm had revenue of $223.80 million for the quarter, compared to analyst estimates of $204.51 million. Lantheus had a negative net margin of 6.89% and a positive return on equity of 19.83%. The business’s quarterly revenue was up 121.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.11 earnings per share.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on LNTH. B. Riley began coverage on shares of Lantheus in a research report on Monday, May 9th. They set a “buy” rating and a $91.00 target price for the company. Truist Financial boosted their target price on shares of Lantheus from $77.00 to $94.00 in a research report on Monday, May 2nd. Finally, SVB Leerink boosted their target price on shares of Lantheus from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Friday.
Insiders Place Their Bets
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. raised its position in shares of Lantheus by 17.0% during the 4th quarter. Principal Financial Group Inc. now owns 555,077 shares of the medical equipment provider’s stock worth $16,036,000 after purchasing an additional 80,665 shares during the last quarter. Sciencast Management LP acquired a new position in shares of Lantheus during the 1st quarter worth about $307,000. Assenagon Asset Management S.A. raised its position in shares of Lantheus by 332.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 251,845 shares of the medical equipment provider’s stock worth $13,930,000 after purchasing an additional 193,585 shares during the last quarter. Congress Wealth Management LLC DE acquired a new position in shares of Lantheus during the 4th quarter worth about $6,329,000. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Lantheus during the 4th quarter worth about $9,534,000. Institutional investors and hedge funds own 97.14% of the company’s stock.
Lantheus Stock Performance
The stock has a market cap of $5.39 billion, a price-to-earnings ratio of -137.84 and a beta of 0.79. The company has a current ratio of 1.83, a quick ratio of 1.64 and a debt-to-equity ratio of 0.31. The firm’s 50-day moving average is $67.85 and its two-hundred day moving average is $55.56.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.